NEW YORK (GenomeWeb News) – The US Food and Drug Administration has approved Roche's companion diagnostic test for Tarceva (erlotinib), Roche announced Tuesday night.

Roche also said that FDA approved Tarceva as a first-line treatment for patients with metastatic non-small cell lung cancer whose tumors have certain epidermal growth factor receptor mutations as detected by the Cobas EGFR Mutation Test.

Tarceva is jointly marketed in the US by Roche's Genentech business and Astellas Pharma US, a subsidiary of Tokyo-based Astellas Pharma.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

The New York Times editorial board weighs in on scientific research misconduct.